AGÕæÈ˹ٷ½

STOCK TITAN

Ani Pharmaceutic SEC Filings

ANIP NASDAQ

Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing FDA warnings, patent cliffs, or controlled-substance quotas in ANI Pharmaceuticals� disclosures can feel like decoding another language. Each annual report blends clinical trial data, DEA quota details, and manufacturing risk factors that easily surpass 200 pages. If you have ever searched for “ANI Pharmaceuticals insider trading Form 4 transactions� or tried to locate one footnote on steroid revenue, you know the challenge.

Stock Titan turns those challenges into clarity. Our platform delivers AI-powered summaries the moment an ANI Pharmaceuticals quarterly earnings report 10-Q filing or 8-K hits EDGAR, highlighting revenue by therapeutic class, fresh FDA correspondence, and supply-chain updates. Need real-time alerts? We surface ANI Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive buys and sells minutes after they post. From the ANI Pharmaceuticals annual report 10-K simplified to every ANI Pharmaceuticals 8-K material events explained, you receive concise language, key metrics, and cross-linked definitions—no accounting degree required.

Below you will find every filing type�10-K, 10-Q, 8-K, S-8, DEF 14A—each paired with an AI snapshot that answers the questions investors actually ask: cash flows by product line, R&D spend on rare-disease assets, or how “ANI Pharmaceuticals proxy statement executive compensation� aligns with pipeline milestones. Use our tools to:

  • Run an “ANI Pharmaceuticals earnings report filing analysisâ€� in seconds
  • Track “ANI Pharmaceuticals executive stock transactions Form 4â€� before market open
  • Master “understanding ANI Pharmaceuticals SEC documents with AIâ€� without sifting through PDFs

Whether you are hunting for segment profitability or compliance triggers, Stock Titan delivers ANI Pharmaceuticals SEC filings explained simply—so you focus on decisions, not document digging.

Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
current report
-
Rhea-AI Summary

ANI Pharmaceuticals (ANIP) � Form 4 filing, 21 Jul 2025. Sr. VP, General Counsel & Secretary Meredith W. Cook reported a tax-related share withholding transaction on 18 Jul 2025.

  • Transaction type: Code F (shares withheld to satisfy taxes on vested restricted stock).
  • Securities affected: 2,071 common shares at an implied price of $66.30, total â‰� $0.14 million.
  • Post-transaction holding: Cook now directly owns 76,874 common shares.
  • Derivative positions: No derivative transactions reported; prior option/RSU holdings unchanged.

The filing reflects routine tax withholding rather than an open-market sale. Cook retains >97% of her pre-vesting equity stake, signalling continued alignment with shareholders. No impact on the company’s operations, earnings outlook or governance structure was disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Prospect Capital Corporation (PSEC) intends to issue three new series of senior unsecured Prospect Capital InterNotes® under its shelf registration (File No. 333-269714):

  • 7.500% Notes due 7/15/2028 (CUSIP 74348GWF3)
  • 7.750% Notes due 7/15/2030 (CUSIP 74348GWG1)
  • 8.000% Notes due 7/15/2032 (CUSIP 74348GWH9)

Each tranche will be sold in $1,000 denominations at modest discounts to par (selling concessions 1.125% / 1.700% / 1.950%) and will accrue interest from the 7/24/2025 settlement date, payable semi-annually on 1/15 and 7/15, commencing 1/15/2026. The notes are callable at 100% of principal beginning 1/15/2026 and daily thereafter. A Survivor’s Option allows early repayment upon the death of the beneficial owner, subject to annual volume caps.

The offering is being marketed by InspereX (purchasing agent) with Citigroup and RBC Capital Markets as agents. Net proceeds (after concessions) were not disclosed in dollar terms but will be used for general corporate purposes.

Capital structure implications: As of 2/8/2023, PSEC had $1.9 billion of unsecured senior debt and $0.7 billion of secured debt outstanding. The new issuance will add incremental fixed-rate leverage at coupons materially above the company’s prior 3.7%â€�6.4% public notes, signalling a higher cost of capital environment. Management recently refinanced its $342.9 million 3.706% 2026 notes—tendering $135.7 million and redeeming the remaining $207.2 million—thus eliminating that maturity but replacing it with higher-coupon paper.

Recent portfolio activity: Between May 29 and July 1, 2025, PSEC sold $324.6 million (cost basis) of subordinated structured notes for $74.6 million in gross proceeds, extended $39.6 million of first-lien financing to National Property REIT Corp. and received $19 million in repayments. On 6/30/2025 the company closed the acquisition of QC Holdings, Inc., investing $55 million in senior secured debt and $22.3 million in common equity.

Company profile: PSEC is an externally managed BDC with $7.9 billion in assets and 130 portfolio companies/CLO positions as of 12/31/2022. The performing interest-bearing portfolio yielded 12.9% (10.3% overall). The credit facility (outstanding $744.7 million on 2/8/2023) is secured and structurally senior to the new notes.

Key investor considerations:

  • High coupons (7.5%-8.0%) increase interest expense but lock in fixed funding before the Federal Reserve’s next rate cycle shift.
  • Notes rank pari passu with existing unsecured obligations and are effectively subordinated to secured debt.
  • Indenture contains limited protective covenants; no change-of-control put or financial maintenance tests.
  • Liquidity events—callable at par after 6 months—introduce reinvestment risk if rates fall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Union Pacific Corp. (UNP) â€� Form 4 insider transaction

EVP Marketing & Sales Kenyatta G. Rocker reported two small open-market acquisitions on 10 July 2025 that were executed through the company’s 2021 Employee Stock Purchase Plan:

  • 12.87 UNP common shares purchased directly at an indicated price of $237 per share.
  • 3.025 UNP common shares purchased indirectly by the reporting person’s spouse at the same price.

Following these transactions, the executive’s beneficial ownership totals:

  • Direct: 52,224.9767 shares
  • Indirect â€� Spouse: 1,265.8917 shares
  • Indirect â€� Deferral Account: 350 shares
  • Indirect â€� Managed Account: 2,031.7113 shares

No derivative security activity or dispositions were disclosed. The filing is administrative in nature and does not indicate any change in strategy or outlook by Union Pacific.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

United Rentals, Inc. (NYSE: URI) and several international subsidiaries executed a Fifth Amended and Restated Credit Agreement on 10 July 2025, replacing their prior asset-based revolver.

The agreement establishes a senior secured $4.5 billion asset-based loan (ABL) facility backed by first-priority liens on substantially all U.S. and certain non-U.S. assets. A $175 million ANZ tranche, along with sub-limits of $250 million for Canada and $125 million for Rest-of-World borrowers, plus multiple swing-line and LC sub-limits, provide multi-currency flexibility (USD, CAD, EUR, GBP and others).

Maturity: 10 July 2030. Drawn as of 9 July 2025: $2.049 billion. Availability: roughly $2.428 billion (net of LCs) subject to borrowing-base limits.

Pricing ranges:

  • SOFR / SONIA / EURIBOR / Term CORRA + 1.00%â€�1.25%
  • Base or Canadian prime + 0.00%â€�0.25%
  • Unused line fee: 0.20%

Covenants & Security: Standard negative covenants on debt, liens, dividends, investments and M&A. No ongoing financial covenant unless availability falls below 10% for five consecutive business days, at which point a 1.0× fixed-charge coverage ratio springs into effect. Guarantees are provided by Holdings and extensive U.S. and international subsidiaries, with collateral including equity pledges (65% limit on voting shares of foreign subs).

Strategic Impact: The new facility extends URI’s debt maturity profile by five years, increases global liquidity, and keeps covenant pressure light under normal operating conditions—supporting working-capital needs, fleet investment and potential bolt-on acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration

FAQ

What is the current stock price of Ani Pharmaceutic (ANIP)?

The current stock price of Ani Pharmaceutic (ANIP) is $67.48 as of July 25, 2025.

What is the market cap of Ani Pharmaceutic (ANIP)?

The market cap of Ani Pharmaceutic (ANIP) is approximately 1.4B.

What is the core business of ANI Pharmaceuticals?

ANI Pharmaceuticals develops, manufactures, and markets both branded and generic prescription drugs, with a focus on complex formulations and niche therapeutic areas.

Which therapeutic segments does ANI Pharmaceuticals specialize in?

The company specializes in high-barrier segments such as controlled substances, oncolytic agents, hormones, steroids, and formulations for rare diseases.

Where are ANI Pharmaceuticals' manufacturing facilities located?

ANI Pharmaceuticals operates its advanced manufacturing facilities in Minnesota, which are compliant with strict FDA and cGMP standards.

How does ANI Pharmaceuticals maintain regulatory compliance?

The company adheres to stringent FDA guidelines and uses sophisticated manufacturing processes to ensure that all products meet high safety and quality standards.

What differentiates ANI Pharmaceuticals from its competitors?

ANI stands out due to its integrated business model, focus on complex formulations, niche market strategies, and robust manufacturing capabilities that target high-barrier therapeutic areas.

How does ANI Pharmaceuticals contribute to the rare disease sector?

ANI has a dedicated rare disease portfolio that focuses on developing innovative therapeutics to address unmet medical needs, ensuring precise treatment solutions for conditions often overlooked by larger players.

What role does research and development play at ANI Pharmaceuticals?

R&D is central to ANI’s operations; the company invests in innovation to continually develop novel therapeutic solutions and improve existing formulations, meeting dynamic healthcare demands.

What strategic value does ANI Pharmaceuticals offer to stakeholders?

ANI offers a balanced approach combining operational excellence, high-quality product manufacturing, and specialization in niche markets, which contributes to sustainable growth and long-term value creation.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Stock Data

1.45B
18.03M
11.22%
97.42%
11.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
BAUDETTE